Jon Snodgres Net Worth

The estimated Net Worth of Jon Snodgres is at least 14.6 百万$ dollars as of 16 February 2023. Mr. Snodgres owns over 5,647 units of Repligen stock worth over 4,205,205$ and over the last 10 years he sold RGEN stock worth over 8,509,040$. In addition, he makes 1,876,610$ as Chief Financial Officer at Repligen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Snodgres RGEN stock SEC Form 4 insiders trading

Jon has made over 21 trades of the Repligen stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 5,647 units of RGEN stock worth 1,129,400$ on 16 February 2023.

The largest trade he's ever made was exercising 31,753 units of Repligen stock on 26 November 2018 worth over 861,141$. On average, Jon trades about 2,725 units every 49 days since 2014. As of 16 February 2023 he still owns at least 29,325 units of Repligen stock.

You can see the complete history of Mr. Snodgres stock trades at the bottom of the page.

Jon Snodgres biography

Jon K. Snodgres serves as Chief Financial Officer of the Company. Mr. Snodgres was previously with Maquet Cardiovascular, a medical device company, where he served as CFO for five years. At Maquet, in addition to being responsible for the preparation and oversight of the company’s financial statements, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a B.S. in Business Administration, Finance from Northern Arizona University.

What is the salary of Jon Snodgres?

As the Chief Financial Officer of Repligen, the total compensation of Jon Snodgres at Repligen is 1,876,610$. There are 1 executives at Repligen getting paid more, with Anthony Hunt having the highest compensation of 4,424,560$.

How old is Jon Snodgres?

Jon Snodgres is 54, he's been the Chief Financial Officer of Repligen since 2014. There are 10 older and no younger executives at Repligen. The oldest executive at Repligen Corp. is Thomas Ryan, 78, who is the Independent Director.

What's Jon Snodgres's mailing address?

Jon's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.

Insiders trading at Repligen

Over the last 21 years, insiders at Repligen have traded over 118,224,292$ worth of Repligen stock and bought 160,440 units worth 1,459,521$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Glenn P Muir、Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of 3,015,702$. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth 1,139,034$.

What does Repligen do?

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Complete history of Mr. Snodgres stock trades at Repligen

Repligen executives and stock owners

Repligen executives and other stock owners filed with the SEC include:

• Anthony Hunt,
  President, Chief Executive Officer, Director
• Jon Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Senior Vice President - Research and Development
• Anthony J. Hunt,
  CEO, Pres & Director
• Jon K. Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Sr. VP of R&D
• Karen Dawes,
  Independent Chairperson of the Board
• Glenn Muir,
  Independent Director
• Thomas Ryan,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Rohin Mhatre,
  Independent Director
• Carrie Eglinton,
  Director
• James Slaughter,
  Chief HR Officer
• James R. Bylund,
  Chief Operating Officer
• Christine Gebski,
  Sr. VP of Filtration & Chromatography
• Ken Elmer,
  Global Head of HR
• Rachel Goodrich,
  VP of Marketing
• Stephen Tingley,
  VP of Global Sales
• Squire Servance,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Sondra S. Newman,
  Global Head of Investor Relations
• Jim Bylund,
  Sr. VP of Operations & Information Technology
• Jason K Garland,
  CFO
• Glenn L Md Cooper,
  Director
• James R Rusche,
  Senior Vice President
• John Cox,
  Director
• Howard Benjamin,
  
• Roy T Eddleman,
  10% owner
• Christine Gebski,
  See Remarks
• G William Miller,
  Director
• Timothy Scott Harris,
  
• Barbara Burnim Day,
  Vice President
• Daniel W Muehl,
  CFO
• Partners L P/Ilbiotechnolog...,
  
• Alfred Lewis Goldberg,
  Director
• Walter C Herlihy,
  PRESIDENT, CEO
• Michael A Griffith,
  Director
• Daniel P Witt,
  Vice President
• Jonathan I Lieber,
  CFO
• Earl Webb Henry,
  Director
• William J Kelly,
  Vice President
• Alexander Rich,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Hal Landy,
  Vice President
• Paul Schimmel,
  Director
• Laura Whitehouse,
  Vice President
• Robert J Hennessey,
  Director
• Margaret Pax,
  
• Konstantin Konstantinov,
  
• Martin D Madaus,
  
• James Bylund,
  Chief Operating Officer
• Olivier Loeillot,
  Chief Executive Officer